Table 1.
Family | Individual | Affection | CMM+DN | Mutation status |
R | 3002 | Unaffected | No | None |
R | 3003 | Affected | Yes | CDK4+ |
K | 1001 | Affected | Yes | CDKN2A+ |
K | 1003 | Unaffected | No | None |
D | 1001 | Affected | Yes | CDKN2A+ |
D | 1003 | Unaffected | No | None |
G | 2005 | Affected | Yes | CDKN2A+ |
G | 2006 | Affected | Yes | None |
J | 1002 | Affected | Yes | CDKN2A+ |
J | 3005 | Unaffected | No | None |
AH | 3005 | Affected | Yes | ARF+ |
AH | 3006 | Unaffected | No | None |
S | 1001 | Affected | Yes | CDK4+ |
S | 1003 | Unaffected | No | None |
A2 | 1001 | Affected | Yes | None |
A2 | 1019 | Unaffected | No | None |
ARF, CDKN2A alternative-spliced exon 1β transcript, CDKN2A, cyclin-dependent kinase inhibitor 2A, CDK4, cyclin-dependent kinase 4, CMM, cutaneous malignant melanoma; DN, dysplastic nevi.